BioAge Labs, Inc. (NASDAQ:BIOA) Stock Has Average Price Target of $33.00

BioAge Labs, Inc. (NASDAQ:BIOA) has earned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $33.00.

Several research firms have recently commented on BIOA. Needham & Company LLC reduced their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Jefferies Financial Group set a $21.00 target price on BioAge Labs in a research note on Friday, July 31st. Roth Capital restated a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a research note on Wednesday, September 9th. UBS Group started coverage on BioAge Labs in a research report on Sunday, October 11th. They set a “neutral” rating and a $8.00 price objective for the company. Finally, BTIG Research reissued a “buy” rating and set a $40.00 target price on shares of BioAge Labs in a research note on Tuesday, September 8th.

Hedge Funds Weigh In On BioAge Labs

A number of hedge funds have recently modified their holdings of BIOA. Legal & General Group Plc acquired a new stake in BioAge Labs during the second quarter valued at $84,000. State of Wyoming acquired a new stake in shares of BioAge Labs in the second quarter worth $154,000. The Manufacturers Life Insurance Company bought a new stake in BioAge Labs during the second quarter valued at about $234,000. Bank of Nova Scotia acquired a new stake in shares of BioAge Labs in the first quarter worth $180,000. Finally, Squarepoint Ops LLC increased its holdings in shares of BioAge Labs by 23.3% during the 2nd quarter. Squarepoint Ops LLC now owns 68,436 shares of the company’s stock worth $1,677,000 after purchasing an additional 12,916 shares during the period.

BioAge Labs Price Performance

Shares of BIOA stock opened at $5.10 on Monday. BioAge Labs has a fifty-two week low of $4.81 and a fifty-two week high of $25.95. The stock has a market cap of $234.09 million, a price-to-earnings ratio of -2.14 and a beta of 1.08. The firm’s 50 day moving average price is $7.85 and its two-hundred day moving average price is $14.73.

BioAge Labs (NASDAQ:BIOA) last announced its earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. The business had revenue of $2.45 million for the quarter. On average, equities analysts forecast that BioAge Labs will post -2.49 EPS for the current fiscal year.

BioAge Labs Company Profile

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates.

BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.

Founded in 2015, BioAge is headquartered in Richmond, California, and conducts research and clinical development activities through collaborations and studies involving patients and research sites in multiple regions.